Atara Biotherapeutics (ATRA) Common Equity (2022 - 2025)
Historic Common Equity for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$36.6 million.
- Atara Biotherapeutics' Common Equity rose 5953.79% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.6 million, marking a year-over-year increase of 5953.79%. This contributed to the annual value of -$97.3 million for FY2024, which is 196.31% up from last year.
- As of Q3 2025, Atara Biotherapeutics' Common Equity stood at -$36.6 million, which was up 5953.79% from -$35.0 million recorded in Q2 2025.
- Atara Biotherapeutics' 5-year Common Equity high stood at $257.5 million for Q2 2022, and its period low was -$110.9 million during Q2 2024.
- In the last 4 years, Atara Biotherapeutics' Common Equity had a median value of -$36.6 million in 2025 and averaged $12.9 million.
- In the last 5 years, Atara Biotherapeutics' Common Equity crashed by 158736.25% in 2024 and then surged by 6839.39% in 2025.
- Over the past 4 years, Atara Biotherapeutics' Common Equity (Quarter) stood at $126.6 million in 2022, then crashed by 178.36% to -$99.2 million in 2023, then grew by 1.96% to -$97.3 million in 2024, then skyrocketed by 62.34% to -$36.6 million in 2025.
- Its Common Equity stands at -$36.6 million for Q3 2025, versus -$35.0 million for Q2 2025 and -$55.1 million for Q1 2025.